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UrolithiasisAbstract Objective: The present study investigated the antiurolithiatic effect of standardized
methanolic extract of Biophytum sensitivum (MBS) against calcium oxalate urolithiasis in rats.
Methods: The MBS was standardized for amentoflavone content by HPLC method. Calcium oxa-
late urolithiasis was induced in rats by ethylene glycol–ammonium chloride feeding in drinking
water. Antiurolithiatic activity of MBS was evaluated at three doses (100, 200 and 400 mg/kg) in
curative and preventive regimen by estimating histological changes in kidney and biochemical
changes in urine, serum and kidney homogenate. Cystone (500 mg/kg, p.o.) was used as reference
standard drug.
Results: Ethylene glycol–ammonium chloride feeding caused an increase in urinary volume,
oxalate, total protein, phosphate and uric acid levels, along with a decrease in urinary excretion
of calcium, magnesium and citrate. Supplementation with MBS significantly prevented change in
the urinary excretion of calcium, oxalate, phosphate, total protein, uric acid, magnesium and
citrate. The MBS supplementation prevented the elevation of serum creatinine, uric acid and blood
urea nitrogen levels. The increased calcium, oxalate and phosphate levels in the kidney of lithiatic
control rats were significantly reduced by the MBS supplementation. The MBS supplementation
caused a significant decrease in the lipid peroxidation of kidney tissue. Histological study revealed
minimum damage and less number of calcium oxalate deposits in the kidneys of MBS-treated rats.
Conclusions: These results indicated that the MBS reduced and prevented the growth of urinary
stones. However, cystone (500 mg/kg) is more effective than the MBS (400 mg/kg) in alleviating
the urolithiasis. This finding supports the traditional use of B. sensitivum for urolithiasis.
 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.ampus,
162 A.T. Pawar, N.S. Vyawahare1. Introduction
The incidences of urolithiasis have increased across the globe in
the last five decades and now urolithiasis has been rated as third
prevalent disorder in the urinary system. Urinary calculi may
cause serious medical consequences such as obstruction,
hydronephrosis, infection and hemorrhage in the urinary tract
system if left untreated.1 Approximately 80% of these calculi
are composed of calcium oxalate and phosphate.2 In modern
medicine, surgical operation, lithotripsy and local calculus dis-
ruption using high-power laser are common treatment options
to remove the calculi. However, these procedures are associated
with serious complications such as acute renal injury, decreased
renal function, increased stone recurrence, etc.3 The recurrence
rate without preventive treatment is approximately 10% at
1 year, 33% at 5 year and 50% at 10 years which is the most
important aspect to be addressed.4
Medicinal plants remain an important alternative source of
new drugs. In the indigenous systems of medicine, a number of
plants have been claimed to be efficient to cure and correct uri-
nary stones.5 These plants and their products are also reported
to be effective in the treatment as well as prevention of recur-
rence of renal calculi with minimal or no side effects.6 As per
the Indian traditional system of medicine, Ayurveda, the whole
plant of Biophytum sensitivum is claimed for its usefulness in
the treatment of various health aliments including urinary
stones.7,8 B. sensitivum (Family: Oxalidaceae) is distributed
in tropical Asia, Africa, America and Philippines. It is found
up to an altitude of 1800 m.8 It has been extensively studied
for its biological activities and therapeutic potentials such as
analgesic, anti-pyretic, anti-inflammatory, immunomodula-
tory, antitumor, antidiabetic, antioxidant, antibacterial, anti-
hypertensive, chemoprotective, radioprotective, antifertility,
etc.9 However, so far no scientific study has been reported
regarding the antiurolithiatic potential of the plant. In this
study, we investigated antiurolithiatic activity of standardized
whole plant extract of B. sensitivum against calcium oxalate
urolithiasis and extrapolated its possible underlying mecha-
nisms using male Wistar albino rats.
2. Materials and methods
2.1. Animals
Male Wistar albino rats weighing between 150 and 250 g were
used for the study. They were procured from National Insti-
tute of Biosciences, Pune, India. The animals were allowed
for acclimatization for ten days under standard conditions in
the CPCSEA (Committee for the Purpose of Control and
Supervision of Experiments on Animals, India) approved ani-
mal house of MAEER’s Maharashtra Institute of Pharmacy,
Pune, India. The animals were given standard diet supplied
by Nutrivet Life Sciences, Pune, India. The study protocol
was approved by the Institutional Animal Ethics Committee
(Ref. No.: MIP/IAEC/2013-14/M1/Appr/003) of MAEER’s
Maharashtra Institute of Pharmacy, Pune, India.
2.2. Chemicals and apparatus
Amentoflavone (Sigma–Aldrich, Germany; B. No.:
BCBD3849V), ethylene glycol (Qualigens Fine Chemicals,India; B. No.: 75316806-2), ammonium chloride (Analab Fine
Chemicals, India; B. No.: RKC221713), and cystone (The
Himalaya Drug Company, India; B. No.: 19300259F) were used
for the study. All other chemicals and reagents used were of
analytical grade and procured from approved vendors. Appara-
tus such as the metabolic cages (New Neeta Chemicals, India),
cold centrifuge (BioEra, India) and UV-spectrophotometer
(LabIndia, India) were used in the study.
2.3. Collection of plant material and preparation of extract
The whole plant material of B. sensitivum was collected from
the local region of Pune, India. It was authenticated by Dr.
J. Jayanthi, Scientist, Botanical Survey of India, Pune, India.
Thereafter, the plant material was washed and shade dried at
room temperature. The dried whole plant was coarsely
powdered, packed into soxhlet column and extracted with
70% v/v methanol in water at 65–70 C for 22 h. This
methanolic extract of B. sensitivum (MBS) was then
evaporated at 45 C and then dried in oven. The dried extract
was stored in an airtight container.
2.4. Standardization of MBS by HPLC
The MBS was standardized for the content of marker com-
pound, amentoflavone by HPLC method.10 Standard solution
of amentoflavone and sample solution of MBS were prepared
in DMSO at the concentration of 10 and 100 lg/ml respec-
tively. Separate chromatograms were obtained for standard
and MBS solution using an HPLC system consisting a binary
pump (Model: Waters 515 HPLC pump), auto sample (Model:
717 plus auto-sampler), column heater and PDA detector
(Waters 2998). Separation was achieved on Kromasil C-18
(250 mm  4.6 mm, 5.0 lm) column maintained at 25 C using
column oven. Isocratic elution with acetonitrile: phosphate
buffer (30:70) mobile phase at the flow rate of 0.7 ml/min
was carried out. The detection was monitored at 330 nm.
Data collection and analysis were performed using
Empower-version 2 software.
2.5. Experimental design
Ethylene glycol and ammonium chloride-induced hyperox-
aluria model was used to induce urolithiasis in rats.11 Three
dose levels of MBS (100, 200 and 400 mg/kg) were used for
the evaluation of its antiurolithiatic effect.12 Animals were ran-
domly divided into ten groups each containing six animals.
Group I served as vehicle control, animals of this group were
maintained on standard rat food and drinking water ad libitum
and received vehicle, i.e. 5% w/v gum acacia solution (5 ml/kg,
p.o.). All the remaining groups received calculi inducing treat-
ment for the period of 28 days, comprised of 0.75% v/v ethy-
lene glycol with 1% w/v ammonium chloride in drinking water
ad libitum for the period of 3 days to accelerate lithiasis
followed by only 0.75% v/v ethylene glycol for next 25 days.
Group II served as lithiatic control and received 5% w/v
gum acacia solution (5 ml/kg, p.o.). Group III served as the
preventive standard treatment group and received cystone
(500 mg/kg) from 1st day to 28th day of calculi induction.
Group IV served as the curative standard treatment group
and received cystone (500 mg/kg) from 14th day to 28th day
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tive treatment groups and received MBS at doses of 100, 200
and 400 mg/kg respectively from 1st day to 28th day of calculi
induction. Groups VIII, IX and X served as curative treatment
groups and received MBS at doses of 100, 200 and 400 mg/kg
respectively from 14th day to 28th day of calculi induction.
The extract and standard drug were suspended in 5% w/v
gum acacia solution and given once daily by oral route
(5 ml/kg body weight).
2.6. Collection and analysis of urine
All animals were kept in individual metabolic cages and 24 h
urine samples were collected on 0, 14 and 28th day of calculi
inducing treatment. The collected urine samples were analyzed
for their volume, calcium, oxalate,13 phosphate,14 magne-
sium,15,16 uric acid,17 citrate18 and total protein19 contents.
The urine calcium level was estimated using kit from Beacon
Diagnostic Pvt. Ltd., India. The 3 h urine samples collected
on 28th day were also subjected to crystalluria study to esti-
mate the presence of calcium oxalate crystals by viewing under
light microscope.
2.7. Serum analysis
After 28th day urine collection period, blood was collected
from retro-orbital sinus under ether anesthesia. Serum was
separated by centrifugation at 10,000g for 10 min and analyzed
for creatinine, uric acid and blood urea nitrogen (BUN) spec-
trophotometrically by using diagnostic kit from Beacon
Diagnostic Pvt. Ltd., India.
2.8. Kidney tissue analysis
After blood collection, all animals were sacrificed by
cervical dislocation. The abdomen was cut open to remove
both kidneys from each animal. Isolated kidneys were
cleaned of extraneous tissue, rinsed in ice-cold physiological
saline and used for tissue homogenate and histopathological
analysis.
2.8.1. Homogenate analysis
The left kidney was finely minced and 20% homogenate was
prepared in Tris–HCl buffer (0.02 mol/l, pH 7.4). The kidney
homogenate was used to analyze tissue calcium, oxalate,13
phosphate14 and lipid peroxidation levels. Calcium in tissue
homogenate was estimated using kit from Beacon Diagnostic
Pvt. Ltd., India. Tissue lipid peroxidation was evaluated by
measurement of thiobarbituric acid reactive substances.20
Briefly, 1.0 ml of kidney homogenate was pipetted into a glass
test tube of 5 ml and incubated at 37 ± 1 C in a water bath
shaker for 60 min at 120 strokes per minute. After 1 h of incu-
bation, 1.0 ml of 5% w/v trichloroacetic acid solution and
1.0 ml of 0.67% w/v thiobarbituric acid solution were added.
The reaction mixture was centrifuged at 3500 rpm for
15 min. The supernatant was transferred to another tube and
placed in a boiling water bath for 10 min. Thereafter, the test
tubes were cooled and the absorbance of the color was read at
535 nm. The results were expressed as percent lipid
peroxidation.2.8.2. Histopathology
The right kidney was fixed in 10% neutral buffered formalin,
processed in a series of graded alcohol and xylene, embedded
in paraffin wax, sectioned at 5 lm and stained with Hema-
toxylin and Eosin for examination under light microscope to
estimate damage index (DI). The histological changes such
as congestion, hemorrhages, focal tubular swelling, granular
and vacuolar changes in cytoplasm, tubular degeneration,
sloughing of tubular epithelium, cystic tubular changes, necro-
tic changes of tubular epithelium, infiltration of mononuclear
cells, glomerular changes and interstitial fibrosis were observed
for damage index with semiquantitative grading system as
grade 0-no visible changes, grade 1-minimal changes
(<25%), grade 2-mild changes (25–50%), grade 3-moderate
changes (51–75%) and grade 4-severe changes (>75%). The
kidney section was also stained by Pizzolato’s method,21 which
selectively stains calcium oxalate crystals, and observed under
light microscope to estimate the total number of calcium oxa-
late deposits.
To estimate DI and number of calcium oxalate deposits, a
sagittal section of each renal specimen was divided into 8 equal
sized regions by four virtual lines according to previously
reported method.22 A 100 field of Hematoxylin and Eosin
stained slide was then randomly selected from each region,
graded for damage index and average of eight readings was
reported as damage index for each specimen. The total area
of each region was used for the counting of calcium oxalate
deposits and the sum of eight readings was reported as total
number of calcium oxalate deposits for each specimen.
2.9. Statistical analysis
All the results were expressed as mean ± standard error of
mean (SEM). The statistical significance was assessed using
one-way analysis of variance (ANOVA) followed by Dunnett’s
comparison test and p< 0.05 was considered significant.3. Results
The yield of MBS was found to be 25% w/w. The HPLC chro-
matogram of MBS showed two major peaks namely P1 and P2
corresponding to retention time 3.50 and 4.85 min respectively
(Fig. 1). The peak P1 was identified as amentoflavone by com-
paring with HPLC chromatogram of reference standard of
amentoflavone showing peak at 3.53 min. The peak P2 was
unidentified peak of some other phytoconstitutent of the plant.
Based on peak area, percent content of amentoflavone in MBS
was found to be 0.09% w/w.
The urine volume was significantly (p< 0.001) increased by
calculi-inducing treatment to rats (Table 1). Treatment of ani-
mals with lower and intermediate doses of MBS (100 and
200 mg/kg) in curative as well as preventive regimen caused
a significant decrease in urine volume than that of calculi-
induced animals. Urine volume of animals treated with cystone
and higher dose of MBS (400 mg/kg) was found similar to that
of calculi-induced animals.
In urine microscopy, no calcium oxalate crystals were seen
in the urine of the vehicle control animals (Fig. 2). The calculi-
inducing treatment induced dipyramid shaped calcium oxalate
crystalluria. Treatment of animals with cystone and all doses
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crystal size in a dose dependent manner.
Calculi-inducing treatment caused significant (p< 0.001)
increase in urinary oxalate, total protein, phosphate and uric
acid levels (Table 1). Increased urinary oxalate, total protein,
phosphate and uric acid levels were significantly decreased
by treatment with cystone and with all doses of MBS in cura-
tive as well as preventive regimen in a dose dependent manner.
The preventive treatment of MBS was found to be more potent
than its curative treatment, in reducing urinary oxalate, total
protein and phosphate levels.
Urinary calcium, magnesium and citrate levels were
significantly (p< 0.001) decreased in calculi-induced animals
than those of vehicle control animals (Table 2). Treatment of
animals with cystone and all doses of MBS in curative as well
as preventive regimen caused a significant and dose-dependent
increase in urinary calcium, magnesium and citrate levels than
that of calculi-induced animals. The preventive treatment of
MBS was found to be more potent than its curative treatment,
in increasing urinary calcium level.
Serum creatinine, uric acid and BUN levels were signifi-
cantly (p< 0.001) increased by the calculi-inducing treatment
(Table 3). Increased serum creatinine, uric acid and BUN
levels were significantly reduced by treatment with cystone
and with all doses of MBS in curative as well as preventive reg-
imen in a dose dependent manner. The preventive treatment of
MBS was found to be more potent than its curative treatment,
in reducing serum uric acid and BUN levels.
Calcium, oxalate and phosphate levels in kidney tissue were
significantly (p< 0.001) increased in calculi-induced animals
than those of vehicle control animals (Table 3). Increased kid-
ney calcium, oxalate and phosphate levels were significantly
decreased by cystone and MBS treatment in curative as well
as preventive regimen in a dose dependent manner. The
preventive treatment of MBS was found to be more potent
than its curative treatment, in reducing phosphate level in
the kidney tissue.
Calculi-inducing treatment caused a significant (p< 0.001)
increase in lipid peroxidation of kidney tissue, which was pre-
vented in the animals treated with cystone and all doses of
MBS in both curative as well as preventive regimen in a dose
dependent manner (Table 3).Figure 1 High performance liquid chromatograph (HPLC) of
(A) MBS standardized to amentoflavone (P1) at RT = 3.50 min
(B) reference standard (amentoflavone) at RT = 3.53 min.Kidneys of calculi-induced animals showed marked histo-
logical changes (Fig. 3) resulting in a significant (p< 0.001)
increase in the damage index (Table 3). Many calcium oxalate
deposits and dilatation of the tubules along with interstitial
fibrosis with dense infiltration of mononuclear cells were
observed in the kidneys of calculi-induced animals. All these
histological changes and damage index were significantly
(p< 0.001) reduced and restored near to normal by the treat-
ment with cystone and all doses of MBS in both curative and
preventive regimen. Pizzolato’s staining method revealed the
presence of calcium oxalate deposits (stained black) in tubules
of all regions of the kidney (cortex, medulla and papilla) of
calculi-induced animals. However, such deposits were small
and less abundant in kidneys of animals treated with MBS
as compared to those in the calculi-induced kidneys (Fig. 4).4. Discussion
A number of animal models using rats have been used to
induce calcium oxalate urolithiasis.23 The most reliable and
hence commonly employed method is to provide ethylene
glycol and ammonium chloride in drinking water to rats.
Therefore, we evaluated the antiurolithiatic potential of
B. sensitivum on calcium oxalate urolithiasis using this model.
The biochemical mechanisms of ethylene glycol and ammo-
nium chloride-induced lithiasis are related to an increase in
the urinary concentration of oxalate. Ethylene glycol is readily
absorbed along the intestine and is metabolized in the liver to
oxalate leading to hyperoxaluria. The oxalate precipitates in
the urine as calcium oxalate due to its poor solubility. High
oxalate levels and calcium oxalate crystals especially in
nephron damage epithelial cells, leading to heterogeneous
nucleation followed by causing aggregation of crystals.24,25
Furthermore, ammonium chloride has been reported to
accelerate lithiasis.26
Male rats were selected to induce urolithiasis because the
urinary system of male rats has more resemblance to that of
humans. In addition, earlier studies have reported that the
amount of stone deposition in female rats was significantly less
compared to male rats.27
In accordance with previous reports, an increase in urine
volume was observed in calculi-induced animals.11,28 The
MBS treatment also increased urine volume but less than
calculi-induced animals. This may be due to diuretic effect of
MBS which reduced calcium oxalate supersaturation in the
urine and thereby stone formation. The exact cause may
be revealed upon overall results, however irrespective of the
mechanism enhanced urine output is beneficial to restore the
condition suggesting that MBS claim has potential.
As reported in some previous publications, calculi-inducing
treatment caused an increase in oxalate and a decrease in cal-
cium excretion in the urine.11,29 Hyperoxaluria is a more signif-
icant risk factor in the pathogenesis of renal stone. In the
present study, the MBS treatment reduced the rate of alter-
ation of this oxalate and calcium excretion. This indicates that
MBS acts by inhibiting some steps of oxalate synthesis.
Consistent with some earlier findings, decreased level of
urinary citrate was observed in calculi-induced animals.11
Hypocitraturia is the major metabolic abnormality in patients
with renal stones. In the present study, the rate of decrease in
citrate excretion was reduced by MBS treatment in a dose
Table 1 Effect of Biophytum sensitivum extract on urine volume, oxalate, total protein, phosphate and uric acid levels in urolit iasis induced rats.
Days Group I Group II Group III Group IV Group V Group VI Group VII Group VIII Group IX Group X
Volume (ml/24 h)
0 7.33 ± 0.36 8.20 ± 0.55 7.83 ± 0.32 7.50 ± 0.45 8.98 ± 0.55 7.90 ± 0.46 8.10 ± 0.44 8.23 ± 0.43 7.83 ± 0.47 8.07 ± 0.53
14 7.20 ± 0.25 19.48 ± 1.39c 20.42 ± 1.35 20.15 ± 1.05 11.27 ± 1.02c 13.40 ± 1.02b 16.43 ± 1.03 20.05 ± 1.07 19.33 ± 1.08 20.15 ± 1.11
28 7.58 ± 0.27 19.75 ± 1.41c 21.33 ± 1.22 20.78 ± 0.96 12.80 ± 0.96c 15.73 ± 0.86a 17.88 ± 1.12 11.72 ± 0.78c 14.67 ± 0.82c 16.20 ± 0.90a
Oxalate (mg/24 h)
0 5.14 ± 0.22 5.41 ± 0.29 5.25 ± 0.26 5.10 ± 0.31 5.27 ± 0.24 5.18 ± 0.28 5.34 ± 0.27 5.22 ± 0.25 5.32 ± 0.33 4.93 ± 0.25
14 5.23 ± 0.28 8.29 ± 0.36c 5.47 ± 0.29c 8.08 ± 0.28 6.78 ± 0.31b 6.06 ± 0.28c 5.68 ± 0.27c 8.21 ± 0.30 7.91 ± 0.28 8.13 ± 0.30
28 5.21 ± 0.25 10.22 ± 0.33c 5.77 ± 0.28c 6.35 ± 0.23c 7.99 ± 0.29c 6.69 ± 0.24c 5.93 ± 0.25c 8.86 ± 0.28b 8.54 ± 0.27c 7.93 ± 0.23c
Total protein (mg/24 h)
0 5.86±.27 5.81 ± 0.27 5.90 ± 0.38 5.94 ± 0.40 5.68 ± 0.25 5.70 ± 0.31 6.02 ± 0.35 6.01 ± 0.32 5.75 ± 0.36 6.08 ± 0.37
14 5.71 ± 0.37 11.00 ± 0.64c 6.10 ± 0.42c 10.65 ± 0.70c 7.56 ± 0.49c 6.81 ± 0.47c 6.40 ± 0.41c 11.09 ± 0.54 11.18 ± 0.65 11.24 ± 0.54
28 5.97 ± 0.35 12.99 ± 0.73c 6.39 ± 0.41c 7.10 ± 0.38c 8.99 ± 0.51c 7.91 ± 0.46c 7.18 ± 0.38c 9.68 ± 0.56b 8.28 ± 0.58c 7.54 ± 0.43c
Phosphate (mg/24 h)
0 5.56 ± 0.23 5.61 ± 0.20 5.66 ± 0.28 5.76 ± 0.18 5.24 ± 0.17 5.46 ± 0.22 5.32 ± 0.20 5.99 ± 0.23 5.45 ± 0.25 5.77 ± 0.19
14 5.57 ± 0.18 6.69 ± 0.29a 5.68 ± 0.23a 6.76 ± 0.22 6.15 ± 0.27 5.90 ± 0.25 5.71 ± 0.22a 6.80 ± 0.24 6.77 ± 0.20 6.74 ± 0.25
28 5.84 ± 0.19 7.56 ± 0.21c 5.74 ± 0.23c 6.02 ± 0.29c 6.17 ± 0.24c 5.94 ± 0.23c 5.78 ± 0.30c 6.42 ± 0.29a 6.10 ± 0.31b 5.93 ± 0.31c
Uric acid (mg/24 h)
0 1.40 ± 0.04 1.47 ± 0.07 1.45 ± 0.04 1.51 ± 0.05 1.57 ± 0.04 1.48 ± 0.04 1.54 ± 0.04 1.44 ± 0.05 1.33 ± 0.04 1.42 ± 0.07
14 1.36 ± 0.06 2.11 ± 0.15b 1.54 ± 0.11a 2.11 ± 0.14 1.81 ± 0.13 1.73 ± 0.12 1.63 ± 0.13 2.09 ± 0.16 2.09 ± 0.09 2.05 ± 0.17
28 1.38 ± 0.04 2.51 ± 0.07c 1.66 ± 0.05c 1.76 ± 0.05c 1.99 ± 0.05c 1.86 ± 0.05c 1.73 ± 0.05c 2.07 ± 0.06c 1.94 ± 0.05c 1.81 ± 0.05c
Values are expressed as mean ± SEM, n= 6, Group I: vehicle control; Group II: lithiatic control; Group III: preventive treatment with stone at 500 mg/kg; Group IV: curative treatment with
cystone at 500 mg/kg; Groups V, VI and VII: preventive treatment with MBS at 100, 200 and 400 mg/kg respectively; Groups VIII, IX and : curative treatment with MBS at 100, 200 and 400 mg/
kg respectively. P-values: a<0.05; b<0.01; c<0.001. Values of Group-II were compared with Group-I and those of Group-III to Group with Group-II.
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Figure 2 The calcium oxalate crystals, viewed under light microscope (400), in 3 h urine from animals of (A) vehicle control; (B)
lithiatic control; (C) preventive treatment with cystone at 500 mg/kg; (D) curative treatment with cystone at 500 mg/kg; (E)–(G) preventive
treatment with MBS at 100, 200 and 400 mg/kg respectively; (H)–(J) curative treatment with MBS at 100, 200 and 400 mg/kg respectively.
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Table 2 Effect of B. sensitivum extract on urinary calcium, magnesium and citrate levels in urolithiasis induced rats.
Days Group I Group II Group III Group IV Group V Group VI Group VII Group VIII Group IX Group X
Calcium (mg/24 h)
0 0.60 ± 0.02 0.58 ± 0.03 0.56 ± 0.02 0.52 ± 0.03 0.61 ± 0.03 0.53 ± 0.03 0.54 ± 0.02 0.59 ± 0.02 0.54 ± 0.02 0.61 ± 0.02
14 0.58 ± 0.03 0.24 ± 0.01c 0.52 ± 0.02c 0.24 ± 0.02 0.41 ± 0.02c 0.45 ± 0.03c 0.50 ± 0.02c 0.25 ± 0.02 0.23 ± 0.01 0.24 ± 0.01
28 0.60 ± 0.02 0.16 ± 0.01c 0.51 ± 0.02c 0.28 ± 0.01c 0.25 ± 0.01c 0.34 ± 0.01c 0.41 ± 0.01c 0.21 ± 0.01a 0.27 ± 0.01c 0.29 ± 0.01c
Magnesium (mg/24 h)
0 2.37 ± 0.09 2.26 ± 0.11 2.66 ± 0.13 2.56 ± 0.09 2.70 ± 0.13 2.57 ± 0.11 2.67 ± 0.10 2.42 ± 0.10 2.35 ± 0.09 2.59 ± 0.13
14 2.71 ± 0.08 1.65 ± 0.17b 2.60 ± 0.09c 1.63 ± 0.16 2.31 ± 0.09b 2.48 ± 0.11c 2.55 ± 0.10c 1.71 ± 0.14b 1.64 ± 0.13 1.66 ± 0.16
28 2.67 ± 0.11 1.46 ± 0.04c 2.54 ± 0.10c 2.42 ± 0.09c 2.17 ± 0.09c 2.33 ± 0.09c 2.48 ± 0.10c 2.09 ± 0.08c 2.26 ± 0.09c 2.40 ± 0.08c
Citrate (mg/24 h)
0 5.57 ± 0.13 5.77 ± 0.25 5.71 ± 0.24 5.98 ± 0.18 6.02 ± 0.16 6.00 ± 0.23 5.64 ± 0.23 5.80 ± 0.24 5.86 ± 0.21 5.68 ± 0.19
14 5.90 ± 0.23 3.49 ± 0.32c 4.69 ± 0.37 3.15 ± 0.30 3.95 ± 0.33 4.17 ± 0.39 4.56 ± 0.24 3.37 ± 0.34 3.42 ± 0.23 3.22 ± 0.38
28 5.83 ± 0.24 2.31 ± 0.08c 5.28 ± 0.21c 4.91 ± 0.22c 4.61 ± 0.21c 4.88 ± 0.18c 5.07 ± 0.22c 4.03 ± 0.17c 4.49 ± 0.21c 4.80 ± 0.20c
Values are expressed as mean ± SEM, n= 6, Group I: vehicle control; Group II: lithiatic control; Group III: preventive treatment with stone at 500 mg/kg; Group IV: curative treatment with
cystone at 500 mg/kg; Groups V, VI and VII: preventive treatment with MBS at 100, 200 and 400 mg/kg respectively; Groups VIII, IX and X curative treatment with MBS at 100, 200 and 400 mg/kg
respectively. P-values: a<0.05; b<0.01; c<0.001. Values of Group-II were compared with Group-I and those of Group-III to Group-X ith Group-II.
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Table 3 Effect of B. sensitivum extract on serum and kidney parameters in urolithiasis induced rats.
Parameters Group I Group II Group III Group IV Group V Group VI Group VII Group VIII Group IX Group X
Serum
Creatinine (mg/dl) 0.70 ± 0.03 1.77 ± 0.08c 0.81 ± 0.04c 0.98 ± 0.05c 1.31 ± 0.06c 1.16 ± 0.05c 0.90 ± 0.05c 1.37 ± 0.06c 1.21 ± 0.06c 1.09 ± 0.05c
Uric acid (mg/dl) 1.49 ± 0.04 5.30 ± 0.13c 2.21 ± 0.06c 2.55 ± 0.06c 4.54 ± 0.09c 3.36 ± 0.08c 2.48 ± 0.07c 4.81 ± 0.09b 3.85 ± 0.08b 2.78 ± 0.06c
BUN (mg/dl) 37.57 ± 0.71 51.21 ± 1.34c 40.05 ± 0.77c 42.71 ± 0.84c 44.64 ± 0.94c 42.88 ± 0.80c 41.81 ± 0.76c 45.48 ± 1.02b 44.57 ± 0.94c 43.69 ± 0.86c
Kidney
Calcium (mg/g) 0.14 ± 0.01 0.33 ± 0.02c 0.15 ± 0.01c 0.16 ± 0.01c 0.21 ± 0.01c 0.18 ± 0.01c 0.16 ± 0.01c 0.23 ± 0.02c 0.20 ± 0.01c 0.17 ± 0.01c
Oxalate (mg/g) 1.34 ± 0.10 5.86 ± 0.18c 1.48 ± 0.10c 2.28 ± 0.11c 3.77 ± 0.13c 2.81 ± 0.12c 1.81 ± 0.11c 4.43 ± 0.15c 3.32 ± 0.14c 2.40 ± 0.11c
Phosphate (mg/g) 2.36 ± 0.10 3.81 ± 0.15c 2.50 ± 0.11c 2.60 ± 0.11c 2.93 ± 0.12c 2.64 ± 0.11c 2.57 ± 0.11c 3.10 ± 0.12b 2.78 ± 0.12c 2.69 ± 0.12c
Lipid peroxidation (%) 30.26 ± 0.82 100.00 ± 4.56c 43.48 ± 1.33c 49.19 ± 1.68c 60.70 ± 2.18c 55.85 ± 1.48c 49.57 ± 1.74c 71.54 ± 3.16c 64.69 ± 2.46c 57.67 ± 2.00c
CaOx deposits (No.) 0.00 ± 0.00 90.85 ± 2.76c 4.56 ± 0.50c 8.92 ± 1.29c 26.85 ± 1.54c 15.08 ± 2.46c 6.38 ± 0.85c 31.29 ± 1.87c 19.08 ± 1.23c 10.17 ± 1.15c
Damage index (arbitrary units) 0.00 ± 0.00 3.02 ± 0.09c 0.21 ± 0.03c 0.56 ± 0.06c 2.02 ± 0.07c 1.19 ± 0.11c 0.19 ± 0.04c 2.25 ± 0.09c 1.50 ± 0.11c 0.60 ± 0.06c
Values are expressed as mean ± SEM, n= 6, Group I: vehicle control; Group II: lithiatic control; Group III: preventive treatment with cystone at 500 mg/kg; Group IV: curative treatment with
cystone at 500 mg/kg; Groups V, VI and VII: preventive treatment with MBS at 100, 200 and 400 mg/kg respectively; Groups VIII, IX and X: curative treatment with MBS at 100, 200 and 400 mg/
kg respectively. P-values: b<0.01; c<0.001. Values of Group-II were compared with Group-I and those of Group-III to Group-X with Group-II.
1
6
8
A
.T
.
P
a
w
a
r,
N
.S
.
V
y
a
w
a
h
a
re
Figure 3 Microscopic images of kidney sections under light microscope (100) after Hematoxylin and Eosin staining from animals of
(A) vehicle control; (B) lithiatic control; (C) preventive treatment with cystone at 500 mg/kg; (D) curative treatment with cystone at
500 mg/kg; (E)–(G) preventive treatment with MBS at 100, 200 and 400 mg/kg respectively; (H)–(J) curative treatment with MBS at 100,
200 and 400 mg/kg respectively.
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Figure 4 Microscopic images of kidney sections under light microscope (100) after Pizzolato’s staining from animals of (A) vehicle
control; (B) lithiatic control; (C) preventive treatment with cystone at 500 mg/kg; (D) curative treatment with cystone at 500 mg/kg; (E)–
(G) preventive treatment with MBS at 100, 200 and 400 mg/kg respectively; (H)–(J) curative treatment with MBS at 100, 200 and 400 mg/
kg respectively.
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tubular citrate reabsorption which is reported as the main
mechanism regulating citrate excretion in lithiatic patients.30
An increase in urinary phosphate excretion was observed in
calculi-induced animals. Previous study reports showed that
increased urinary phosphate excretion along with oxalate
stress provides an environment suitable for stone formation
by forming calcium phosphate crystals, which induces calcium
oxalate deposition.30,31 The MBS treatment showed to
decrease the rate of urinary phosphate excretion and thereby
reduced the risk of stone formation.
Urinary magnesium excretion was decreased in calculi-
induced animals as reported in some earlier findings.11 Magne-
sium is one of the urinary inhibitors of crystallization. Low
levels of magnesium are also encountered in stone-forming rats
as well as in patients with renal stones. In addition, it is
observed that magnesium levels return to normal on drug
treatment in renal stone patients.31 Diets high in magnesium
have been found to protect against deposition of calcium oxa-
late in the kidneys of vitamin B6 deficient rats. The beneficial
effects in preventing recurrence of stone have been shown in
patients treated with potassium ammonium citrate. Magne-
sium is reported to form a complex with oxalate and reduce
the supersaturation of calcium oxalate by reducing the satura-
tion of calcium oxalate and as a consequence reduce the
growth and nucleation rate of calcium oxalate crystals.30,31
In the present study, the MBS treatment restored the magne-
sium excretion near to normal and thus reduced the growth
of calcium oxalate crystals. The crystallization inhibitory
potential of MBS, as evident from the examination of the crys-
talluria, thus could be the result of increased magnesium con-
tent of the urine of MBS treated rats.
The increase in urinary uric acid excretion was observed in
calculi-induced animals. Increased uric acid excretion has been
reported in kidney stone patients and hyperoxaluric rats. Uric
acid is reported to interfere with calcium oxalate solubility. It
also binds and reduces the inhibitory activity of glycosamino-
glycans.31 The predominance of uric acid crystals in calcium
oxalate stones and the observation that uric acid binding pro-
teins are capable of binding to calcium oxalate and modulate
its crystallization also suggest its primary role in stone forma-
tion.30,31 Treatment of MBS reduced the excretion of uric acid
and thereby reduces the risk of stone formation.
Consistent with previous reports, increased urinary protein
excretion was observed in calculi-induced animals.30,31 Super-
saturation of urinary colloids results in precipitation of crystal
initiation particle which when trapped acts as a nidus leading
to subsequent crystal growth. This is associated with protein-
uria that reflects proximal tubular dysfunction.31 Treatment
of MBS showed to minimize the excretion of protein and thus
might have prevented the nidus formation of crystal nucle-
ation. The MBS produced the initial effect of enhancing uri-
nary output, and further showed reduction in protein
excretion which is an indirect indication of either recovery of
urinary dysfunction or prevention of crystal-induced damage.
This action of MBS is considered as the most fruitful outcome
because MBS not only provides symptomatic action but also
has its direct action at membrane level.
Increased lipid peroxidation has been reported in the kid-
neys of rats supplemented with a calculi-producing diet.27 An
elevated urinary oxalate concentration has been reported to
induce lipid peroxidation and cause renal damage by reactingwith polyunsaturated fatty acids in the cell membrane.27,32
This renal damage was indicated by the elevated serum levels
of creatinine, uric acid and BUN which are markers of
glomerular and tubular damage. In the present study, there
was a significant increase in the serum levels of creatinine, uric
acid and BUN of calculi-induced rats. The MBS treatment
showed to prevent the elevation of serum levels of these mark-
ers. This indicates that MBS acts by inhibiting the lipid perox-
idation and thereby reduces the extent of tubular dysfunction.
The glomerular and tubular damage mediated by lipid perox-
idation is another important step in the progress of pathology.
If this is left untreated then the condition becomes worse
through the initiation of a series of complications. The MBS
has shown significant restoration indicating better control on
the progress of pathology which can be termed as important
characteristics to label it as an ideal therapy.
Increased renal calcium, oxalate and phosphate levels were
observed in calculi-induced animals as reported earlier.27,28
Treatment of MBS showed to prevent this increase in renal cal-
cium, oxalate and phosphate levels. This shows that MBS also
inhibits the retention of stone in the renal tubules.
Microscopic examination of kidney sections of calculi-
induced animals showed accumulation of calcium oxalate
deposits inside the tubules which causes marked histological
changes such as dilation of the proximal tubules along with
interstitial inflammation. The MBS treatment decreased the
number and size of calcium oxalate deposits in different parts
of renal tubules and also reduced damages to the renal tubules.
This may be in part due to the antioxidant effect of the plant.33
Cystone, a marketed antiurolithiatic composite herbal
preparation, is reported to have a protective effect on calcium
oxalate urolithiasis. It prevents the accumulation, deposition
and supersaturation of stone forming constituents, and
thereby inhibits the formation of kidney stones.34 Cystone also
dissolves kidney stones by causing dissolution of mucin which
is responsible to bind the stone particles together.35 Further-
more, it has a diuretic action that flushes out comparatively
smaller stones from kidneys.36 In the present study, both pre-
ventive as well as curative regimens of MBS were effective in
reducing the risk of stone formation, decreasing renal tissue
injury, reducing the crystal size and thus, facilitating easy
expulsion and restoring normal kidney architecture. However,
the preventive effect of MBS was more effective than its cura-
tive treatment. This may be due to more potent antiaggrega-
tory effect of MBS on stone forming constituents than its
effect on dissolution of preformed stones, suggesting prefer-
able use of MBS in prevention of kidney stones, especially in
cases of recurrence.5. Conclusion
The present investigation supports the use of B. sensitivum in
folk medicine against urolithiasis. It is concluded that adminis-
tration of whole plant extract of B. sensitivum reduced and pre-
vented the growth of urinary stones. It also seems that the
preventive effect is more effective than its curative treatment.
Therefore, the whole plant extract of B. sensitivum is helpful
to prevent the recurrence of the disease. The mechanism under-
lying this effect is mediated collectively through diuretic,
antioxidant, and nephroprotective properties and lowering
the concentration of urinary stone-forming constituents.
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